Axitinib combined with K drug treatment

Axitinib (Axitinib combined with K-drug treatment is an innovative treatment plan for advanced renal cell carcinoma (RCC), which combines the dual advantages of targeted therapy and immunotherapy, bringing new treatment hopes and possibilities to patients.

Axitinib is an oralVEGFR (vascular endothelial growth factor receptor) inhibitor that slows the growth and spread of tumors by inhibiting angiogenesis in tumor cells. Drug K (pembrolizumab) is a PD-1 inhibitor that can activate the patient's own immune system to attack tumor cells. When these two drugs are used in combination, they can produce a powerful synergistic effect, attacking tumor cells from multiple angles and improving the therapeutic effect.

In clinical studies, axitinib combined with K drug treatment has shown significant efficacy. The results of a randomized, open-label clinical phase III study called KEYNOTE-426 showed that compared with sunitinib alone, the combination treatment regimen had significant advantages in overall survival (OS) and progression-free survival (PFS). Specifically, the median OS in the combination therapy group reached 47.2 months, compared with 40.8 months in the sunitinib group; the median PFS in the combination therapy group was 15.7 months, compared with 11.1 months in the sunitinib group. These data fully prove the efficacy of axitinib combined with K drug treatment.

In addition to the significant efficacy, axitinib combined with K drug treatment also has good safety. Although this treatment option may cause some side effects, such as high blood pressure, proteinuria, diarrhea, etc., most of these side effects are controllable and can be effectively managed under the guidance of a doctor.

In general, axitinib combined with K drug treatment is an efficient and safe treatment option for advanced renal cell carcinoma. It attacks tumor cells by inhibiting angiogenesis of tumor cells and activating the immune system, which can significantly improve patients' survival and quality of life. However, since this treatment option may have certain side effects, a comprehensive evaluation and examination is required before use, and it must be used under the guidance of a doctor.